Differential secretion of glucagon-like and somatostatin-like immunoreactivity from the perfused eel pancreas in response to D-glucose

Protein and lipid metabolism adjustments in silver catfish (Rhamdia quelen) during different periods of fasting and refeeding

The fish may experience periods of food deprivation or starvation which produce metabolic changes. In this study, adult Rhamdia quelen males were subjected to fasting periods of 1, 7, 14, and 21 days and of refeeding 2, 4, 6, and 12 days. The results demonstrated that liver protein was depleted after 1 day of fasting, but recovered after 6 days of refeeding. After 14 days of fasting, mobilization in the lipids of the muscular tissue took place, and these reserves began to re-establish themselves after 4 days of refeeding. Plasmatic triglycerides increased after 1 day of fasting, and decreased following 2 days of refeeding. The glycerol in the plasma oscillated constantly during the different periods of fasting and refeeding. Changes in the metabolism of both protein and lipids during these periods can be considered as survival strategies used by R. quelen. The difference in the metabolic profile of the tissues, the influence of the period of fasting, and the type of reserves mobilized were all in evidence.

Regulation of somatostatins and their receptors in fish

The multifunctional nature of the somatostatin (SS) family of peptides results from a multifaceted signaling system consisting of many forms of SS peptides that bind to a variety of receptor (SSTR) subtypes. Research in fish has contributed important information about the components, function, evolution, and regulation of this system. Somatostatins or mRNAs encoding SSs have been isolated from over 20 species of fish. Peptides and deduced peptides differ in their amino acid chain length and/or composition, and most species of fish possess more than one form of SS. The structural heterogeneity of SSs results from differential processing of the hormone precursor, preprosomatostatin (PPSS), and from the existence of multiple genes that give rise to multiple PPSSs. The PPSS genes appear to have arisen through a series of gene duplication events over the course of vertebrate evolution. The numerous PPSSs of fish are differentially expressed, both in terms of the distribution among tissues and in terms of the relative abundance within a tissue. Accumulated evidence suggests that nutritional state, season/stage of sexual maturation, and many hormones [insulin (INS), glucagon, growth hormone (GH), insulin-like growth factor-I (IGF-I), and 17beta-estradiol (E2)] regulate the synthesis and release of particular SSs. Fish and mammals possess multiple SSTRs; four different SSTRs have been described in fish and several of these occur as isoforms. SSTRs are also wide spread and are differentially expressed, both in terms of distribution of tissues as well as in terms of relative abundance within tissues. The pattern of distribution of SSTRs may underlie tissue-specific responses of SSs. The synthesis of SSTR mRNA and SS-binding capacity are regulated by nutritional state and numerous hormones (INS, GH, IGF-I, and E2). Accumulated evidence suggests the possibility of both tissue- and subtype-specific mechanisms of regulation. In many instances, there appears to be coordinate regulation of PPSS and of SSTR; such regulation may prove important for many processes, including nutrient homeostasis and growth control.

The expression of preprosomatostatin II mRNAs in the Brockmann bodies of rainbow trout, Oncorhynchus mykiss, is regulated by glucose

We previously characterized two cDNAs that encode for distinct preprosomatostatin molecules containing [Tyr(7), Gly(10)]-somatostatin-14 at their C-termini (PPSS II' and PPSS II") and found that these cDNAs were differentially expressed in the endocrine pancreas (Brockmann body) of rainbow trout, Oncorhynchus mykiss. In this study, we examined the control of PPSSII' mRNA and PPSS II" mRNA expression by glucose. Fish injected with glucose displayed elevated plasma levels of glucose in association with nearly three-fold higher levels of PPSS II mRNAs compared to saline-injected control animals. Glucose directly stimulated the expression of both PPSS II mRNAs in vitro in a dose-dependent manner; however, glucose was a more potent stimulator of PPSS II" expression than of PPSS II' expression. The hexoses, mannose, galactose, and fructose, as well as glucose, all induced the expression of PPSS II mRNAs, whereas, sucrose and the glucose analogs, 3-o-methylglucose and 2-deoxyglucose, were without effect. In addition, the expression of PPSS II mRNAs was stimulated by dihydroxyacetone, pyruvate, lactate, acetate, and citrate. Furthermore, the expression of PPSS II mRNAs was inhibited by iodoacetate, an inhibitor of glycolysis, but was stimulated by dichloroacetate, a stimulator of Krebs cycle flux via pyruvate dehydrogenase activation. Finally, glucose-stimulated PPSS II expression was inhibited by actinomycin. These results indicate that the expression of PPSS II mRNAs in the Brockmann body of trout is regulated by nutrients such as glucose and suggest that glucose-stimulated expression of PPSS II mRNAs requires the uptake and subsequent metabolism of the sugar and is transcription sensitive.

Glucose regulates pancreatic preprosomatostatin I expression

Rainbow trout were used as a model system to evaluate the role of glucose in regulating the expression of preprosomatostatin I. Glucose increased pancreatic levels of preprosomatostatin I mRNA in vivo, in concert with elevated plasma somatostatin levels, and in vitro. Glucose-stimulated expression of preprosomatostatin I mRNA required the uptake, phosphorylation, and subsequent metabolism of the sugar in pancreatic islets. These results suggest that glucose modulates both the production and release of somatostatin.

Lipid-stimulated somatostatin secretion in rainbow trout,Oncorhynchus mykiss

Previous work has shown that somatostatins (SS) affect teleost lipid metabolism indirectly by inhibition of insulin (INS) and directly by stimulation of hepatic lipolysis. In the present study, rainbow trout (Oncorhynchus mykiss) were used to characterize further the lipid-SS relationship by evaluating how lipid, contributes to SS secretion bothin vivo andin vitro. In vivo hyperlipidemia was induced for up to 3 h by short-term (2 min) infusion of a triacylglycerol (TG)-rich lipid emulsion (20% Intralipid(®)). Plasma total lipid concentration increased 118 and 155% over control levels 1 h and 3 h, respectively, after infusion; much of this increase was due to elevated plasma fatty acids (FA), which increased 39 and 520%, respectively, over the same time-frame. The hyperlipidemic pattern was attended by a significant increase in the plasma concentration of SS. The specific effects of fatty acids were evaluated on isolated Brockmann bodies. Palmitic acid and oleic acid stimulated SS release 378 and 82%, respectively, over baseline levels. These results indicate that lipids, and in particular fatty acids, modulate SS secretion in rainbow trout.

Glucagon and glucagon-like peptides in fishes

Glucagon and glucagon-like peptides (GLPs) are coencoded in the vertebrate proglucagon gene. Large differences exist between fishes and other vertebrates in gene structure, peptide expression, peptide chemistry, and function of the hormones produced. Here we review selected aspects of glucagon and glucagon-like peptides in vertebrates with special focus on the contributions made by analysis of piscine systems. Our topics range from the history of discovery to gene structure and expression, through primary structures and regulation of plasma concentrations to physiological effects and message transduction. In fishes, the pancreas synthesizes glucagon and GLP-1, while the intestine may contribute oxyntomodulin, glucagon, GLP-1, and GLP-2. The pancreatic gene is short and lacks the sequence for GLP-2. GLP-1, which is produced exclusively in its biologically active form, is a potent metabolic hormone involved in regulation of liver glycogenolysis and gluconeogenesis. The responsiveness of isolated hepatocytes to glucagon is limited to high concentrations, while physiological concentrations of GLP-1 effectively regulate hepatic metabolism. Plasma concentrations of GLP-1 are higher than those of glucagon, and liver is identified as the major site of removal of both hormones from fish plasma. Ultimately, GLP-1 and glucagon exert effects on glucose metabolism that directly and indirectly oppose several key actions of insulin. Both glucagon and GLP-1 show very weak insulinotropic activity, if any, when tested on fish pancreas. Intracellular message transduction for glucagon, especially at slightly supraphysiological concentrations, involves cAMP and protein kinase A, while pathways for GLP are largely unknown and may involve a multitude of messengers, including cAMP. In spite of fundamental differences in GLP-1 function between fishes and mammals, fish GLP-1 is as powerful an insulinotropin for mammalian B-cells as mammalian GLP-1 is a metabolic hormone if tested on piscine liver.

Somatostatin 14- and somatostatin 25-like peptides in pancreatic endocrine cells of Sparus aurata (teleost): a light and electron microscopic immunocytochemical study

An immunocytochemical investigation demonstrates the presence of somatostatin (SST) 14- and salmon somatostatin (sSST) 25-like peptides in two populations of somatostatin (D) cells in the islets of gilthead sea bream (Sparus aurata). Both cell types were identified by their differing immunoreactivities to the somatostatin antisera used. D1 cells in the islet periphery between glucagon cells showed sSST 25-like immunoreactivity and contained large moderate to low electron-dense granules. D2 cells, present only in the central region of the islets between insulin cells, were immunoreactive to the SST 14 antisera and had smaller electron-dense granules. In S. aurata, as in other teleosts, preprosomatostatin I and II are probably synthesized and processed to SST 14- and sSST 25-like peptides, respectively, in different D cell types.

Insulin-receptor binding in skeletal muscle of trout

Two hundred rainbow trout (Oncorhynchus mykiss) age 0 +, weight range 11.3 - 11.5 g, were distributed randomly in two groups and maintained for five weeks on either 10% dextrin, or 20% dextrin diet. The fish were sampled 3-5 h and 18-20 h after the last feeding and insulin binding to partially purified insulin receptors in white and red skeletal muscles and to liver plasma membranes was assessed. Plasma insulin, plasma glucose, and liver glycogen content were analyzed in the same fish.Fish fed a diet with higher carbohydrate content (HC) had elevated insulin and glucose levels in peripheral blood, but lower liver glycogen contents compared to the fish fed a diet with lower carbohydrate content (LC). No growth retardation was observed in the fish from HC group.Three to five hours after the last feeding, insulin-receptor binding in white skeletal muscles was higher in HC group of fish, mostly because of an increase in number of high affinity binding sites. Eighteen to twenty hours after the last feeding this difference disappeared. In contrast, the specific binding of insulin to the liver plasma membranes appeared to be lower in the HC group of fish. The lower insulin binding to the liver plasma membranes observed 3-5 h after feeding, could be attributed to the lower quantity of binding sites, while the same phenomenon 18 h after feeding was likely a result of affinity changes. We conclude that higher glycemic levels observed in trout fed a HC diet as compared to LC group of fish, are not a consequence of impaired binding of insulin to its receptors in skeletal muscles.

Somatostatin-14 and somatostatin-25 stimulate glycogenolysis in rainbow trout, Oncorhynchus mykiss, liver incubated in vitro: a systemic role for somatostatins

The effects of somatostatin-14 (SS-14) and salmon somatostatin-25 (sSS-25) on hepatic glycogenolysis were studied by incubating rainbow trout liver pieces in vitro. Glycogen content in untreated liver pieces cultured for 3 and 5 hr was 28.6 +/- 7.6 mg/g fresh wt. and 21.5 +/- 6.6 U, respectively. Treatment of liver pieces with either SS-14 or sSS-25 resulted in significant glycogen depletion; sSS-25 appeared more potent in this regard. Equimolar concentrations (10(-8) M) of SS-14 or sSS-25 reduced glycogen content to 10.6 +/- 1.6 and 2.6 +/- 2.2 U, respectively, in liver pieces incubated for 3 hr. Alterations in liver glycogen content were reflected in glucose release into medium. Basal release of glucose into culture medium over the course of a 3-hr incubation was 20 +/- 5.6 mumol/g dry wt. Both SS-14 and sSS-25 stimulated a rapid increase (500 and 600%, respectively) in glucose release during the first 0.5 hr of incubation. After 3 hr, SS-14 and sSS-25 stimulated glucose release over basal levels to 116 +/- 9.3 and 153 +/- 16 U, respectively. Both SS-14 and sSS-25 stimulated glucose release in a dose-dependent manner; ED50 for both peptides was ca. 5 X 10(-8) M. These results indicate that both SS-14 and sSS-25 directly mediate hepatic glycogenolysis in rainbow trout.

Radioimmunoassay for salmon pancreatic somatostatin-25

A specific and sensitive radioimmunoassay (RIA) for the measurement of plasma levels of somatostatin-25 (SS-25) in salmon was developed using antisera raised against coho salmon (Oncorhynchus kisutch) SS-25. Somatostatin-25 was iodinated by the chloramine-T method and repurified on Sephadex G-25. The RIA was performed using a double antibody (goat anti-rabbit gammaglobulin as second antibody) method under disequilibrium conditions. Plasma from several salmonids (coho, chinook, rainbow trout, brook trout, arctic char, lake trout, and whitefish) as well as plasma from some nonsalmonids (sucker, bluegill) cross-reacted with the antisera; serial dilutions of plasma from rainbow trout, brook trout, chinook salmon, and coho salmon were parallel to the SS-25 standard curve. Plasma from catfish showed negligible cross-reactivity. None of the mammalian somatostatins (somatostatin-14, somatostatin-28). U II, or other pancreatic hormones (insulin, glucagon) tested showed significant cross-reactivity with the antibody in the assay system. The lowest detectable level of SS-25 was 5 pg/tube; especially reproducible results were obtained in the range of 0.15-1.20 ng/ml, which appears to be the normal range of SS-25 circulating in the plasma of salmonids. Intra- and interassay coefficients of variation were 5.7 and 12.6%, respectively. Injection of glucose into chinook salmon resulted in an elevation of plasma SS-25 titers within 30 min and was coincident with hyperglycemia.

2-Deoxyglucose stimulates the release of insulin and somatostatin from the perfused catfish pancreas

Glucokinase was proposed to function as a glucose sensor in pancreatic B-cells, acting possibly as a pacemaker of the rate of glycolysis. Glucose, mannose, and 2-deoxyglucose are good substrates of glucokinase which are easily taken up into B-cells. Glucose and mannose are well-known stimuli of insulin release in mammals and fish. I report here that 2-deoxyglucose is also a strong stimulus of insulin and somatostatin release from the in vitro perfused pancreas (i.e., splenic Brockmann body) of channel catfish (Ictalurus punctatus). This is surprising because the product of the glucokinase-catalyzed phosphorylation of 2-deoxyglucose. 2-deoxyglucose-6-phosphate, cannot be metabolized further at an appreciable rate. 3-O-Methylglucose, which does not bind appreciably to mammalian glucokinase, stimulated neither insulin nor somatostatin release. Glucosamine, which binds tightly to glucokinase but is phosphorylated only at a very low rate, did not stimulate insulin release either, but did cause a small amount of somatostatin to be released. The results suggest that glucose-activated glucokinase itself may serve as a signal molecule in glucose recognition by B- and D-cells.

Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch

Salmon (Oncorhynchus kisutch) somatostatin (sSS; 4 or 8 ng/g body wt) or synthetic Gillichthys urotensin II (UII; 2 or 4 ng/g body wt) were injected intraperitoneally into juvenile freshwater coho salmon. Both sSS and UII caused a dose-dependent increase in plasma free fatty acids (FFA) which diminished with time. sSS induced an initial (1 hr) transient hyperglycemia. By contrast, UII tended to induce hypoglycemia, this effect being significant 5 hr after injection of the higher dose. Both sSS and UII depressed plasma insulin titers 1 hr after injection. By 3 hr, the sSS-associated insulin depression was no longer observed. UII treatment induced a hyperinsulinemia which was present 3 and 5 hr after peptide administration. Although no decreases in liver total lipid concentration or in mesenteric fat total tissue mass were observed, lipolytic enzyme activity within each depot was significantly enhanced by both peptides. Neither sSS nor UII altered 3H2O incorporation into fatty acids or neutral lipids. However, enhanced lipogenesis, particularly by UII, was indicated by increased NADPH production resulting from glucose-6-phosphate dehydrogenase activity. Both sSS and UII enhanced glucose mobilization, as indicated by decreased liver glycogen content and increased liver glucose-6-phosphatase activity. UII, but not sSS, stimulated glycogen synthetase activity. These results suggest that both sSS and UII stimulate hyperlipidemia by enhancing depot lipase activity and that although both factors are potentially gluconeogenetic, sSS seems to be glycogenolytic and hyperglycemic, whereas UII may channel glucose to FFA synthesis.

Secretagogues for pancreatic hormone release in the channel catfish (Ictalurus punctatus)

We investigated the effect of several potential carbohydrate secretagogues, amino acids, a ketoacid, and potassium chloride on insulin, glucagon, and somatostatin release from the in vitro perfused Brockmann body of channel catfish (Ictalurus punctatus). Mannose (15 mM) stimulated the release of insulin and somatostatin. Fructose (30 mM) induced only a small and transient release of somatostatin. Galactose (15 mM) was not a secretagogue. Likewise, glyceraldehyde failed to stimulate hormone release. Among the amino acids newly tested, alanine and leucine, and also alpha-ketoisocaproic acid were without effect. A high concentration of potassium (25 mEq/liter) induced a pronounced release of insulin and glucagon and a moderate release of somatostatin. In conclusion, a striking similarity exists between catfish and higher vertebrates in their pancreatic endocrine response to hexoses; on the other hand, the catfish Brockmann body appears to respond only to a few of the common stimuli of pancreatic hormone release in mammals.

Plasma glucagon levels in different species of fish

Plasma glucagon levels in 11 different teleosts and in dogfish were evaluated using an adapted classical mammalian radioimmunoassay (RIA). The values obtained are considered relative; sensitivity was inferior to the original method, but the validation experiment results are acceptable. The mean value of the coefficient of the variation for interassay was 6% and for intraassay 4%, recovery was 98%, and a good linearity in the dilution test was found. Some species (Sparus aurata and cyprinids) presented high plasma glucagon concentrations (0.50-1.60 ng/ml) versus the lower levels (0.08-0.40 ng/ml) found in salmonids and others, and the lowest in dogfish (0.02-0.20 ng/ml). A positive correlation (P less than 0.02) between insulin and glucagon plasma levels was found in different species. The low levels obtained in all parameters analyzed in the selachian were remarkable. This adapted RIA could serve as a useful tool in amplifying knowledge on the endocrine pancreatic response in fish in different biological situations.

Characterization of coho salmon (Oncorhynchus kisutch) islet somatostatins

Three different somatostatins have been isolated from the pancreatic islet tissue of the coho salmon (Oncorhynchus kisutch) by gel filtration and HPLC. Two of these peptides contain 14 amino acids and the larger third peptide consists of 25 amino acids. The sequence of the salmon SST-25 is Ser-Val-Asp-Asn-Leu-Pro-Pro-Arg-Glu-Arg-Lys-Ala-Gly -Cys-Lys-Asn-Phe-Tyr-Trp-Lys-Gly-Phe-Thr-Ser-Cys. The sequence of the salmon SST-14-I is Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys. The other small somatostatin (SST-14-II) which was not sequenced has an amino acid composition identical to the C-terminal 14 amino acids of the SST-25 and it is probably derived from this larger form. Evidence for low levels of a somatostatin containing 28 amino acids is also presented. This SST-28 appears to be an N-terminal extended precursor of SST-25 or a peptide derived via alternative processing of a common preprosomatostatin. Injected into juvenile salmon, SST-25 caused a decline in circulating levels of plasma insulin, depletion of liver glycogen, and activation of lipolytic pathways. Juvenile salmon treated with anti-SST-25 serum revealed elevated levels of plasma insulin as well as an increase of the glycogen content of the liver.